A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H.
Abstract | CONTEXT: RESULTS: From September 22, 2008, to December 11, 2011, 35 individuals (80% males, median age 60 y) were enrolled. All patients have been followed up until treatment discontinuation or for a minimum of four cycles. Eight patients (23%) are still on the study treatment. The median number of therapy cycles was eight. Five patients attained partial Response Evaluation Criteria In Solid Tumors responses (14.3%; 90% confidence interval 5.8%-27.7%), with a median progression-free survival and overall survival of 9.4 and 19.9 months, respectively. Side effects included treatment-requiring (new) hypertension (33%), fatigue (14%), diarrhea (9%), and abnormal liver tests (6%); 3 of 35 patients (8.6%) discontinued therapy due to adverse events. There was one death of a study patient after withdrawal from the trial deemed potentially treatment related. CONCLUSIONS:
Pazopanib has promising clinical activity in metastatic MTC with overall manageable toxicities.
|
Authors | Keith C Bible, Vera J Suman, Julian R Molina, Robert C Smallridge, William J Maples, Michael E Menefee, Joseph Rubin, Nina Karlin, Kostandinos Sideras, John C Morris 3rd, Bryan McIver, Ian Hay, Vahab Fatourechi, Jill K Burton, Kevin P Webster, Carolyn Bieber, Anne M Traynor, Patrick J Flynn, Boon Cher Goh, Crescent R Isham, Pamela Harris, Charles Erlichman, Endocrine Malignancies Disease Oriented Group, Mayo Clinic Cancer Center, and the Mayo Phase 2 Consortium |
Journal | The Journal of clinical endocrinology and metabolism
(J Clin Endocrinol Metab)
Vol. 99
Issue 5
Pg. 1687-93
(May 2014)
ISSN: 1945-7197 [Electronic] United States |
PMID | 24606083
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, N.I.H., Extramural)
|
Chemical References |
- Angiogenesis Inhibitors
- Indazoles
- Pyrimidines
- Sulfonamides
- pazopanib
- Receptors, Vascular Endothelial Growth Factor
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors
(adverse effects, therapeutic use)
- Carcinoma, Medullary
(drug therapy, mortality, secondary)
- Disease Progression
- Female
- Humans
- Indazoles
- Male
- Middle Aged
- Pyrimidines
(adverse effects, therapeutic use)
- Receptors, Vascular Endothelial Growth Factor
(antagonists & inhibitors)
- Sulfonamides
(adverse effects, therapeutic use)
- Thyroid Neoplasms
(drug therapy, mortality, pathology)
- Treatment Outcome
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|